Loading...
01/10 17:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates strong revenue growth, successful partnerships, and product line expansions. Despite some uncertainties in supply chain and economic factors, the company remains optimistic about achieving positive EBITDA. The Q&A section further supports this sentiment, highlighting continued sales growth and strategic manufacturing capabilities. The financial performance shows significant improvement in gross profit and margins. While there are some concerns about tariffs and market size estimates, the overall outlook remains positive, suggesting a stock price increase in the short term.
Revenue $2,810,000, an increase of 121% year over year compared to $1,270,000 in Q1 2024. The increase was primarily due to sales growth in both contract manufacturing (up 58%) and consumer branded products (up 189%).
Cost of Revenues $1,620,000, compared to $1,110,000 in Q1 2024. The increase is aligned with the increase in revenue growth.
Gross Profit $1,190,000, compared to $160,000 in Q1 2024. The increase of $1,030,000 was primarily due to the increase in overall sales.
Gross Profit Margin 42.4%, compared to 12.6% in Q1 2024. The increase is attributed to higher sales and the reclassification of Amazon sales commissions into cost of goods sold.
EBITDA Negative $540,000, compared to negative $840,000 in Q1 2024. The narrowing loss is due to substantial growth in both Contract Manufacturing and Consumer Products.
Adjusted EBITDA Negative $470,000, compared to negative $730,000 in Q1 2024. The improvement is attributed to increased sales.
Net Loss $710,000, compared to a net loss of $850,000 in Q1 2024. The reduction in net loss is due to improved revenue and gross profit.
Cash Balance Approximately $1,190,000 as of 03/31/2025.
New Product Launches: Metagel will expand its product line with the anticipated launch of several new offerings, including the SilverSeal Wound and Burn Kit and its moist burn pads. KencoDerm will double its product portfolio in Q3 2025 with new products. Silly George will launch new beauty products including lip gloss, a hydrating lip mask, and under-eye patches.
Market Expansion: NextGel received approval from Health Canada to sell SilverSeal in that territory. The company is also seeing increased interest in U.S. made gels due to tariff implications.
Operational Efficiencies: Gross margins for Q1 normalized to 42.4%, aligning with historical ranges. The company has built inventory for Silly George products in anticipation of tariff changes.
Strategic Shifts: NextGel is exploring the possibility of using a new clean room in Texas for assembly to mitigate potential high tariffs. The company is also focusing on R&D for new applications of hydrogels.
Regulatory Issues: The launch of AbbVie's Resonic machine has been delayed due to manufacturing issues unrelated to NextGel, which could impact revenue expectations.
Supply Chain Challenges: NextGel is monitoring tariff changes, particularly the potential increase from 34% to 145%, which could significantly affect costs. They are considering shifting some manufacturing to Texas if tariffs become unmanageable.
Competitive Pressures: There is increased interest in U.S.-made gels due to tariffs on imported products, which may provide a competitive advantage for NextGel.
Economic Factors: The company is cautious about potential economic downturns that could affect consumer spending, although they currently see no weakness in sales.
Cash Flow Management: NextGel is focused on managing cash appropriately and avoiding debt until they achieve EBITDA positivity, which is expected soon.
Revenue Growth: Revenue for Q1 2025 totaled $2,810,000, a 121% increase year-over-year.
Gross Margin: Gross margins normalized to 42.4%, aligning with historical ranges.
Contract Manufacturing Growth: Contract manufacturing revenue increased 58% year-over-year.
Consumer Products Growth: Consumer branded products revenue increased 189% year-over-year.
New Product Launches: New product launches planned for MetaGel, KencoDerm, and Silly George in 2025.
Strategic Partnerships: Partnership with AbbVie for gel pads and with Innovative Optics for FDA study.
Tariff Management: Monitoring tariffs and exploring local assembly options to mitigate impacts.
Revenue Guidance: Maintaining revenue guidance of $13,000,000 for 2025.
Cash Flow Positivity: Expecting to achieve cash flow positivity in 2025.
EBITDA Expectations: Projected to cross EBITDA positive in the near future.
Market Opportunities: Significant growth potential in contract manufacturing and consumer products.
Shares Outstanding: As of 05/13/2025, NextGel had 7,654,537 shares of common stock outstanding.
The earnings call presents a mixed outlook. Financial performance is stable with improved margins and narrowed losses, but logistical delays and dependence on key partnerships pose risks. The Q&A reveals uncertainties, particularly with AbbVie and logistical challenges, dampening optimism. The reaffirmed guidance and potential positive EBITDA are countered by economic uncertainties and cash flow challenges. Without a clear market cap, the sentiment remains neutral, balancing positive operational efficiencies against logistical and partnership risks.
The earnings call summary and Q&A section reveal strong financial performance, with 121% revenue growth and positive developments in consumer products. Strategic partnerships with major companies like AbbVie suggest future revenue potential despite delays. The company maintains guidance and expects cash flow positivity, indicating financial health. Although there are some uncertainties, like the AbbVie timeline and tariff impacts, the overall sentiment is positive, especially with strong sales from Silly George and new product launches. The positive sentiment outweighs the negatives, suggesting a likely positive stock price movement.
The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.
The earnings call highlights a significant revenue increase, strong gross profit margins, and optimistic future guidance, which are positive indicators. While there are concerns about tariffs and regulatory issues, these are being actively managed. The lack of a shareholder return plan is a minor negative, but the partnership with STADA and the consistent growth in Silly George's margins are strong positives. Overall, the positive financial performance and strategic partnerships outweigh the risks, suggesting a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
